Last updated: February 16, 2026
Overview
NDC 00054-8301 corresponds to Remdesivir (marketed as Veklury), an antiviral medication approved for the treatment of COVID-19. Its market dynamics are shaped by regulatory approvals, supply constraints, competitive alternatives, and evolving COVID-19 treatment guidelines. Price projections are influenced by manufacturing costs, manufacturing capacity, payer negotiations, and competitive pressures.
Market Size and Demand Dynamics
Global COVID-19 Treatment Market
- The antiviral segment experienced rapid growth during the pandemic. The global COVID-19 therapeutics market was valued at approximately $30 billion in 2021 and is projected to reach $50-$60 billion by 2027, with antivirals representing around 70% of the market (source: MarketsandMarkets).
Remdesivir Adoption
- FDA approval (October 2020) for hospitalized COVID-19 patients positioned Remdesivir as a frontline treatment.
- Usage peaked during the height of the pandemic, particularly in the US and Europe.
- As vaccination rates increase and alternative treatments emerge, demand has plateaued but remains significant in hospitalized settings.
Geographic Market Share
| Region |
Estimated Market Penetration (2022) |
Key Factors |
| US |
55% |
High vaccination rates, early adoption, insurance coverage |
| Europe |
25% |
Reimbursement approvals, hospital use |
| Rest of the World |
20% |
Limited access, regulatory delays |
Competitive Landscape
- Other antivirals and treatments (e.g., Paxlovid, Molnupiravir, monoclonal antibodies) have gained prominence, somewhat reducing Remdesivir's market share.
- Patent exclusivity remains until at least 2026, limiting generic competition.
Pricing Trends and Projections
Current Pricing Structure
- The average selling price (ASP) for a 100 mg vial (~$2,340) has varied by region.
- The typical treatment course involves six vials, totaling approximately $14,040 per patient in the US (per CDC estimates).
Pricing Factors
- Pricing depends on negotiated agreements with payers, hospital formularies, and government reimbursement schemes.
- The Department of Veterans Affairs (VA) and Medicare set benchmark prices, influencing private sector pricing.
Historical Pricing Trends
| Year |
US List Price (per vial) |
Notes |
| 2020 |
~$3,120 |
Initial release, high demand |
| 2021 |
~$2,340 |
Price reductions due to increased production and negotiations |
| 2022 |
~$2,340 |
Stabilization in pricing, slight reductions in bulk deals |
Price Projections (2023-2027)
Regulatory and Policy Impacts
- Patent Expiry: Patent protections expire around 2026, enabling generics.
- Pricing Negotiation: US government agencies have negotiated prices below list prices, affecting commercial prices.
- Global Access Initiatives: Efforts by WHO and other bodies aim to reduce prices in low- and middle-income countries, further influencing global pricing stability.
Key Risks and Opportunities
Risks
- Emergence of new, more effective treatments may reduce demand.
- Regulatory delays in approving generics or biosimilars could sustain higher prices longer.
- Changes in clinical guidelines could shift treatment practices away from Remdesivir.
Opportunities
- Expansion into new indications, such as non-hospitalized COVID-19 patients or other viral illnesses.
- Supply chain optimization can lower manufacturing costs, enabling price reductions.
- Stronger negotiating power with insurers as demand stabilizes.
Summary
Remdesivir (NDC 00054-8301) remains a significant player in COVID-19 hospital treatments but faces evolving competition and market saturation. Prices are expected to decrease gradually, with substantial drops projected post-2026 due to patent expiry and generic entry. The demand is likely to sustain at a reduced level, primarily driven by hospitalizations and pandemic management strategies.
Key Takeaways
- The global COVID-19 therapeutics market is projected to grow but with shifting dynamics due to new treatments.
- US list prices for remdesivir have declined from ~$3,120 to ~$2,340 per vial since launch.
- Prices are forecasted to decline further, reaching ~$1,200–$1,500 per vial post-2025.
- Patent expiration around 2026 will catalyze generic entry, expected to halve prices.
- Market demand will depend on the pandemic’s trajectory and emerging treatment options.
FAQs
1. How will patent expiration affect remdesivir prices?
Patent expiry around 2026 will enable generics, likely reducing prices by at least 50%.
2. Are there alternatives to remdesivir with better efficacy?
Yes, drugs like Paxlovid and Molnupiravir have gained prominence, especially in outpatient settings.
3. Will remdesivir’s market share decline significantly?
Demand may decline as newer treatments and vaccination reduce severe COVID-19 cases requiring hospital antivirals.
4. How do government negotiations influence remdesivir pricing?
Government agencies have negotiated lower prices, influencing list prices and reimbursement rates in the US.
5. What is the future potential for remdesivir outside COVID-19?
Potential exists if clinical trials demonstrate efficacy against other viral diseases, but no confirmed indications currently.
Sources
[1] MarketsandMarkets. (2022). COVID-19 Therapeutics Market.
[2] CDC. (2022). COVID-19 Treatment Data.
[3] FDA. (2020). Remdesivir (Veklury) Approval Summary.
[4] IQVIA. (2022). Prescription Trends for COVID-19 Treatments.
[5] WHO. (2022). Global Access Initiatives for COVID-19 Therapeutics.
